Table 1.
Patient | Stadium | Tumour histology | Age | T | N | M | Gleason score/grade* | Surgery | PSA |
---|---|---|---|---|---|---|---|---|---|
Prostate cancer | |||||||||
P1 | II | Adenocarcinoma | 52 | 2c | 0 | 0 | 3+4 | Operable | 3.3 ng/mL; 16.5% |
P2 | II | Adenocarcinoma | 64 | 2c | 0 | 0 | 3+3 | Operable | 2.78 ng/mL; 12% |
P3 | II | Adenocarcinoma | 55 | 2c | 0 | 0 | 4+4 | Operable | 8.2 ng/mL; 8.5% |
Urinary bladder cancer | |||||||||
B1 | 0a | Papillary carcinoma | 64 | a | 0 | 0 | 2 | Operable | n/a |
B2 | I | Papillary carcinoma | 73 | 1 | 0 | 0 | 2 | Operable | n/a |
B3 | 0a | Papillary carcinoma | 76 | a | 0 | 0 | 2 | Operable | n/a |
Kidney cancer | |||||||||
K1 | III | Clarocellulare carinoma | 66 | 3a | 0 | 0 | 3 | Operable | n/a |
K2 | II | Clarocellulare carinoma | 70 | 2 | 0 | 0 | 2 | Operable | n/a |
Gleason score for prostate cancer; grade for Urinary bladder cancer and kidney cancer. PSA: prostate-specific antigen; n/a: not applicable.